On medical therapy for heart failure consistent with prevailing cardiovascular guidelines at a stable dose for ≥4 weeks prior to screening, except for diuretics which must have been stable for ≥2 weeks prior to screening.ACE inhibitors/ARBs, Beta-blockers, Mineralocorticoid receptor antagonist, Loop or high-ceiling diuretics, Thiazides or low ceiling diuretics, Lipid-lowering drugs. The gene discussed is NR3C2; the disease is heart failure.